Ardelyx
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 267
- Market Cap
- $1.4B
- Website
- http://www.ardelyx.com
- Introduction
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
China Approves First-in-Class Tenapanor for Hyperphosphatemia in Dialysis Patients
• Fosun Pharma's Wan Ti Le (tenapanor hydrochloride tablets) has received NMPA approval for controlling serum phosphorus in dialysis patients with chronic kidney disease who have inadequate response to phosphate binders.
• As the world's first and only approved phosphate absorption inhibitor, tenapanor works through a novel mechanism by inhibiting NHE3, reducing intestinal phosphate absorption through the paracellular pathway.
• Clinical studies show tenapanor can decrease serum phosphate levels by an additional 0.57 mmol/L when combined with phosphate binders, potentially addressing the low phosphate control rates (39%) among China's one million hemodialysis patients.
Breakthroughs in Biotech: Promising Developments in Diabetes, Cancer, and Lymphoma Treatments
Recent advancements in the biotech sector highlight significant progress in treatments for diabetes, breast cancer, multiple myeloma, and T cell lymphoma, with several companies receiving FDA approvals or making notable strides in clinical trials.
© Copyright 2025. All Rights Reserved by MedPath